Eric Halioua

Eric Halioua

Company: PDC*line Pharma

Job title: President & CEO

Email: e.halioua@pdc-line-pharma.com

Seminars:

Panel Discussion – Evaluating Combination Therapies to Maximise Anti-Tumour Immune Activity 4:00 pm

• What is the ideal combination strategy for neoantigen vaccines? • What are the best combination therapies that maximise T cell responses and efficacy? • How to identify a clear biologic effect caused by combination • Improving clinical efficacy through immunotherapy combinationsRead more

day: Day Two

Dendritic Cells & Their Role in Immunotherapy 3:00 pm

• Presenting a new class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line (PDC*line) • Discussing a new potent and scalable therapeutic cancer vaccine based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells • Understanding how the PDC*line is much more potent to prime and boost antitumour antigen, including neoantigens,…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.